Robert Roskoski

Summary

Publications

  1. ncbi request reprint Vascular endothelial growth factor (VEGF) signaling in tumor progression
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116A, Box 19, Horse Shoe, NC 28742, USA
    Crit Rev Oncol Hematol 62:179-213. 2007
  2. doi request reprint The ErbB/HER family of protein-tyrosine kinases and cancer
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742, USA Electronic address
    Pharmacol Res 79:34-74. 2014
  3. doi request reprint The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742, USA
    Expert Opin Drug Discov 8:1165-79. 2013
  4. doi request reprint Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742, USA
    Pharmacol Res 68:68-94. 2013
  5. doi request reprint ERK1/2 MAP kinases: structure, function, and regulation
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742, USA
    Pharmacol Res 66:105-43. 2012
  6. doi request reprint MEK1/2 dual-specificity protein kinases: structure and regulation
    Robert Roskoski
    Blue Ridge Institute for Medical Research, Horse Shoe, NC 28742, USA
    Biochem Biophys Res Commun 417:5-10. 2012
  7. doi request reprint RAF protein-serine/threonine kinases: structure and regulation
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742, USA
    Biochem Biophys Res Commun 399:313-7. 2010
  8. ncbi request reprint Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
    Robert Roskoski
    Blue Ridge Institute for Medical Research, Horse Shoe, NC 28742, USA
    Biochem Biophys Res Commun 356:323-8. 2007
  9. doi request reprint VEGF receptor protein-tyrosine kinases: structure and regulation
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116A, Box 19, Horse Shoe, NC 28742, USA
    Biochem Biophys Res Commun 375:287-91. 2008
  10. ncbi request reprint Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor
    Robert Roskoski
    Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, 1100 Florida Avenue, New Orleans, LA 70119, USA
    Biochem Biophys Res Commun 338:1307-15. 2005

Detail Information

Publications11

  1. ncbi request reprint Vascular endothelial growth factor (VEGF) signaling in tumor progression
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116A, Box 19, Horse Shoe, NC 28742, USA
    Crit Rev Oncol Hematol 62:179-213. 2007
    ..Owing to the importance of angiogenesis in tumor progression, inhibition of VEGF signaling represents an attractive cancer treatment...
  2. doi request reprint The ErbB/HER family of protein-tyrosine kinases and cancer
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742, USA Electronic address
    Pharmacol Res 79:34-74. 2014
    ..The role of combinations of targeted drugs or targeted drugs with cytotoxic therapies is being explored in an effort to prevent or delay drug resistance in the treatment of these malignancies. ..
  3. doi request reprint The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742, USA
    Expert Opin Drug Discov 8:1165-79. 2013
    ..Drug discovery efforts increased after finding that about 4% of non-small-cell lung cancers (NSCLCs) possess an EML4-ALK fusion protein...
  4. doi request reprint Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742, USA
    Pharmacol Res 68:68-94. 2013
    ....
  5. doi request reprint ERK1/2 MAP kinases: structure, function, and regulation
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742, USA
    Pharmacol Res 66:105-43. 2012
    ..Thus far, however, only inhibition of mutant B-Raf (Val600Glu) has been found to be therapeutically efficacious...
  6. doi request reprint MEK1/2 dual-specificity protein kinases: structure and regulation
    Robert Roskoski
    Blue Ridge Institute for Medical Research, Horse Shoe, NC 28742, USA
    Biochem Biophys Res Commun 417:5-10. 2012
    ..MEK1 regulation is unusual in that S212 phosphorylation in its activation segment is inhibitory. Moreover, active ERK catalyzes a feedback inhibitory phosphorylation of MEK1 T292 that serves to downregulate the pathway...
  7. doi request reprint RAF protein-serine/threonine kinases: structure and regulation
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742, USA
    Biochem Biophys Res Commun 399:313-7. 2010
    ..C-RAF plays a key role in this paradoxical increase in downstream MEK-ERK activation...
  8. ncbi request reprint Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
    Robert Roskoski
    Blue Ridge Institute for Medical Research, Horse Shoe, NC 28742, USA
    Biochem Biophys Res Commun 356:323-8. 2007
    ..Both sunitinib and imatinib bind reversibly to the ATP binding site of their target kinases and thereby inhibit their catalytic activity...
  9. doi request reprint VEGF receptor protein-tyrosine kinases: structure and regulation
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116A, Box 19, Horse Shoe, NC 28742, USA
    Biochem Biophys Res Commun 375:287-91. 2008
    ..Interaction between VEGFR1 and VEGFR2 or VEGFR2 and VEGFR3 alters receptor tyrosine phosphorylation...
  10. ncbi request reprint Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor
    Robert Roskoski
    Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, 1100 Florida Avenue, New Orleans, LA 70119, USA
    Biochem Biophys Res Commun 338:1307-15. 2005
    ..STI-571 binds to Kit and Bcr-Abl (the oncoprotein of chronic myelogenous leukemia) at their ATP-binding sites...
  11. ncbi request reprint The ErbB/HER receptor protein-tyrosine kinases and cancer
    Robert Roskoski
    Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, 1100 Florida Avenue, New Orleans, LA 70119, USA
    Biochem Biophys Res Commun 319:1-11. 2004
    ..An ErbB2/HER2 ectodomain directed antibody (trastuzumab, or Herceptin) has also been approved for the treatment of breast cancer. Current research promises to produce additional agents based upon these approaches...